Literature DB >> 24082455

Non transferrin bound iron: nature, manifestations and analytical approaches for estimation.

Meghna Patel1, D V S S Ramavataram.   

Abstract

Iron is an essential trace element and plays a number of vital roles in biological system. It also leads the chains of pathological actions if present in excess and/or present in free form. Major portion of iron in circulation is associated with transferrin, a classical iron transporter, which prevent the existence of free iron. The fraction of iron which is free of transferrin is known as "non transferrin bound iron". Along with the incidence in iron over loaded patient non transferrin bound iron has been indicated in patients without iron overload. It has been suggested as cause as well as consequence in a number of pathological conditions. The major organs influenced by iron toxicity are heart, pancreas, kidney, organs involved in hematopoiesis etc. The most commonly suggested way for iron mediated pathogenesis is through increased oxidative stress and their secondary effects. Generation of free oxygen radicals by iron has been well documented in Fenton chemistry and Haber-Weiss reaction. Non transferrin bound iron has obvious chance to generate the free reactive radicals as it is not been shielded by the protective carrier protein apo transferrin. The nature of non transferrin bound iron is not clear at present time but it is definitely a group of heterogenous iron forms free from transferrin and ferritin. A variety of analytical approaches like colorimetry, chromatography, fluorimetry etc. have been experimented in different research laboratories for estimation of non transferrin bound iron. However the universally accepted gold standard method which can be operated in pathological laboratories is still to be developed.

Entities:  

Keywords:  Apo transferrin; Fenton chemistry; Haber–Weiss reaction; Non transferrin bound iron; Oxidative stress; Transferrin

Year:  2012        PMID: 24082455      PMCID: PMC3477448          DOI: 10.1007/s12291-012-0250-7

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  111 in total

1.  Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy.

Authors:  W Breuer; M J Ermers; P Pootrakul; A Abramov; C Hershko; Z I Cabantchik
Journal:  Blood       Date:  2001-02-01       Impact factor: 22.113

2.  Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy.

Authors:  J B Porter; R D Abeysinghe; L Marshall; R C Hider; S Singh
Journal:  Blood       Date:  1996-07-15       Impact factor: 22.113

3.  Computer simulation of chelation therapy. Plasma mobilizing index as a replacement for effective stability constant.

Authors:  P M May; D R Williams
Journal:  FEBS Lett       Date:  1977       Impact factor: 4.124

4.  Improved quantification for non-transferrin-bound iron measurement using high-performance liquid chromatography by reducing iron contamination.

Authors:  Katsunori Sasaki; Katsuya Ikuta; Hiroki Tanaka; Takaaki Ohtake; Yoshihiro Torimoto; Mikihiro Fujiya; Yutaka Kohgo
Journal:  Mol Med Rep       Date:  2011-06-27       Impact factor: 2.952

5.  Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development.

Authors:  M R Loken; V O Shah; K L Dattilio; C I Civin
Journal:  Blood       Date:  1987-11       Impact factor: 22.113

Review 6.  Iron-mediated cardiovascular injury.

Authors:  L D Horwitz; E A Rosenthal
Journal:  Vasc Med       Date:  1999       Impact factor: 3.239

Review 7.  Iron and atherosclerosis.

Authors:  L Y Chau
Journal:  Proc Natl Sci Counc Repub China B       Date:  2000-10

8.  Dietary iron intake and risk of coronary disease among men.

Authors:  A Ascherio; W C Willett; E B Rimm; E L Giovannucci; M J Stampfer
Journal:  Circulation       Date:  1994-03       Impact factor: 29.690

9.  Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1.

Authors:  F N al-Refaie; D G Wickens; B Wonke; G J Kontoghiorghes; A V Hoffbrand
Journal:  Br J Haematol       Date:  1992-10       Impact factor: 6.998

10.  Labile plasma iron in iron overload: redox activity and susceptibility to chelation.

Authors:  Breno P Esposito; William Breuer; Pornpan Sirankapracha; Pensri Pootrakul; Chaim Hershko; Z Ioav Cabantchik
Journal:  Blood       Date:  2003-06-12       Impact factor: 22.113

View more
  18 in total

Review 1.  Potential scenarios leading to ovarian cancer arising from endometriosis.

Authors:  Hiroshi Kobayashi
Journal:  Redox Rep       Date:  2016-02-15       Impact factor: 4.412

2.  Snapshots of Iron Speciation: Tracking the Fate of Iron Nanoparticle Drugs via a Liquid Chromatography-Inductively Coupled Plasma-Mass Spectrometric Approach.

Authors:  Heather M Neu; Sergei A Alexishin; Joel E P Brandis; Anne M C Williams; Wenjing Li; Dajun Sun; Nan Zheng; Wenlei Jiang; Ann Zimrin; Jeffrey C Fink; James E Polli; Maureen A Kane; Sarah L J Michel
Journal:  Mol Pharm       Date:  2019-02-14       Impact factor: 4.939

3.  First study on iron complexes in blood and organ samples from thalassaemic and normal laboratory mice using Mössbauer spectroscopy.

Authors:  George Charitou; Vlassis Petousis; Charalambos Tsertos; Yannis Parpottas; Marina Kleanthous; Marios Phylactides; Soteroula Christou
Journal:  Eur Biophys J       Date:  2017-07-10       Impact factor: 1.733

4.  Metabolomics approach based on LC-HRMS for the fast screening of iron(II)-chelating peptides in protein hydrolysates.

Authors:  Cédric Paris; Katalin Selmeczi; Bruno Ebel; Loic Stefan; Gizella Csire; Céline Cakir-Kiefer; Stéphane Desobry; Laetitia Canabady-Rochelle; Patrick Chaimbault
Journal:  Anal Bioanal Chem       Date:  2021-01-02       Impact factor: 4.142

5.  Iron commensalism of mesenchymal glioblastoma promotes ferroptosis susceptibility upon dopamine treatment.

Authors:  Vu T A Vo; Sohyun Kim; Tuyen N M Hua; Jiwoong Oh; Yangsik Jeong
Journal:  Commun Biol       Date:  2022-06-16

6.  Serum iron levels increased by cancer chemotherapy correlate the chemotherapy-induced nausea and vomiting.

Authors:  Toshimichi Miya; Haruhiko Kondo; Akihiko Gemma
Journal:  Int J Clin Oncol       Date:  2018-07-24       Impact factor: 3.402

Review 7.  Alteration of Iron Concentration in Alzheimer's Disease as a Possible Diagnostic Biomarker Unveiling Ferroptosis.

Authors:  Eleonora Ficiarà; Zunaira Munir; Silvia Boschi; Maria Eugenia Caligiuri; Caterina Guiot
Journal:  Int J Mol Sci       Date:  2021-04-25       Impact factor: 5.923

8.  Catalytic ferrous iron in amniotic fluid as a predictive marker of human maternal-fetal disorders.

Authors:  Yuka Hattori; Takahiro Mukaide; Li Jiang; Tomomi Kotani; Hiroyuki Tsuda; Yukio Mano; Seiji Sumigama; Tasuku Hirayama; Hideko Nagasawa; Fumitaka Kikkawa; Shinya Toyokuni
Journal:  J Clin Biochem Nutr       Date:  2014-11-01       Impact factor: 3.114

9.  A novel approach to quantify different iron forms in ex-vivo human brain tissue.

Authors:  Pravin Kumar; Marjolein Bulk; Andrew Webb; Louise van der Weerd; Tjerk H Oosterkamp; Martina Huber; Lucia Bossoni
Journal:  Sci Rep       Date:  2016-12-12       Impact factor: 4.379

10.  Antiviral effects of ferric ammonium citrate.

Authors:  Hongbin Wang; Zheng Li; Junling Niu; Yongfen Xu; Li Ma; Ailing Lu; Xun Wang; Zhikang Qian; Zhong Huang; Xia Jin; Qibin Leng; Jianhua Wang; Jin Zhong; Bing Sun; Guangxun Meng
Journal:  Cell Discov       Date:  2018-03-27       Impact factor: 10.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.